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Zusammenfassung  
Um Liposomen aus Nanoemulsionen herzustellen, wird ein 
Zentrifugationsverfahren entwickelt, das eine hohe Einkapselungseffizienz 
und asymmetrische Membranen ermöglicht. Heparin-Komplexe werden für 
die Bildung einer stabilen Schutzschicht verwendet. Um die Erprobung der 
liposomalen Formulierungen in vitro und in vivo zu ermöglichen, wurden 
Mistelpräparate mit unterschiedlicher Viscotoxin-(VT) und Mistellektin-(ML) 
Zusammensetzung sowie isoliertes ML°I an Maus-Zelllinien erprobt. Ein 
Proliferationstest wurde durchgeführt, um die inhibierenden 
Konzentrationen (IC50) zu ermitteln und sensitive Zelllinien für in vivo 
Experimente auszuwählen. abnobaVISCUM (AV) Pini Präparate, die den 
geringsten Gesamtgehalt an ML und eine Dominanz von ML III aufweisen, 
zeigten bei B16-F10 Melanomzellen eine stärkere Inhibierung der 
Proliferation im Vergleich zu den ML I reichen Präparaten AV Fraxini und 
Quercus. Für AV Fraxnini und AV Quercus wurde gezeigt, dass die 
Zytotoxizität überwiegend auf ML I zurückzuführen ist und ML I daher als 
potentieller Wirkstoff zur Verkapselung in Liposomen geeignet ist. Auf 
isoliertes ML I reagiert die getestete Kolonkarzinomzelllinie C26 deutlich 
empfindlicher als die aggressive B16-F10 Melanomzelllinie. Diese Ergebnisse 
erlauben den Vergleich eines sensitiven mit einem aggressiven Tumormodell 
in vivo. Im Vergleich zu C26 ist die Makrophagenzelllinie RAW264.7 relativ 
unempfindlich gegenüber isoliertem ML I. Die Ergebnisse deuten auf die 
Möglichkeit einer gezielten Therapie von z.B. Kolontumoren hin, bei der die 
Immunfunktionen intakt bleiben. 
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Summary  
A centrifugal technology is under development to produce liposomes from a 
nanoemulsion and to enable high encapsulation efficiencies in asymmetric 
membranes. Heparin complexes are used for a robust protective coating of 
liposomes. To enable in vitro and in vivo testing of liposomal formulations, 
mistletoe preparations with differences in viscotoxin (VT) and mistletoe (ML) 
lectin composition were tested on murine cell lines. A proliferation assay was 
performed to determine the half maximal inhibitory concentration (IC50) 
and select sensitive cell lines for in vivo experiments. abnobaVISCUM (AV) 
Pini preparations, with the lowest total ML content and a ML°III dominated 
composition, showed a stronger inhibition of proliferation on B16-F10 
(mouse melanoma) cells relative to the total ML content compared to AV 
Fraxini and Quercus. ML I is the major cytotoxic component in AV Fraxini and 
AV Quercus and therefore a potential API for encapsulation in liposomes. The 
tested colon carcinoma cell line C26 is significantly more sensitive to isolated 
ML I than the aggressive B16-F10 melanoma cell line. In regard to animal 
models, this allows to compare a sensitive to a relatively non-sensitive and 
more aggressive tumor cell line. In comparison to C26, the macrophage cell 
line RAW264.7 is relatively insensitive to isolated ML I, suggesting the 
possibility of selecting therapeutic concentrations that target e.g. colon 
tumours, but leave immune functions intact.  
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Introduction 
Pharmaceutical flow processes were invented for the production of 
mistletoe preparations in the 1920s (Steiner 1923, Steiner 1924), many 
decades before liposomal preparations in cancer therapy were 
introduced in 1974 (Gregoriadis et al. 1974). The processes inaugurated 
for the preparation of mistletoe injectables bear a high potential for a new 
class of liposomal drug formulations of plant extracts, see Vrânceanu et 
al. 2012. Especially heat and solvent sensitive active pharmaceutical 
ingredients like mistletoe lectins cannot be encapsulated in liposomes by 
any conventional method, but could be loaded into liposomes by adapted 
flow processes initially developed for mistletoe. 
 
Fig. 1: Concept of the pharmaceutical flow process to embed mistletoe 
extracts in liposomes. Extracts are dispersed in an oil phase as an 
emulsion which is centrifuged, thereby forming liposomes. To protect 
against rapid clearance of liposomes by components of innate and 
adaptive immunity and to prolong the half-life of encapsulated API in 
the blood circulation, subsequent surface modifications of liposomes, e.g. 
by coating with heparin conjugates, can be employed (Dührkop et al. 
2016, Han et al. 2006). 
 
Fig. 1 shows the concept of dispersing mistletoe extracts in nanometer 
sized droplets in an oil where phospholipids act as emulsifiers. Once the 
emulsion droplets are transferred through the interface by centrifugal 
forces due to their density difference, they are covered by an additional 
phospholipid monolayer forming bilayers. These biological membranes 
constitute the shell of the liposomes which enclose mistletoe compounds 
and can act as drug delivery systems to reach the tumour tissue by 
extravasation and accumulation. 
In an European project collaboration, the pharmaceutical process 
engineering of liposomal formulations of mistletoe by flow processes is 
studied intensively and major aspects of emulsification are published 
(Hildebrandt et al. 2015, Hildebrandt et al. 2016). The immune reactions 
provoked by liposomes were described by Klapper et al. 2014 with new 
modes of complement activation by phospholipid liposomes being 
elucidated. Approved liposomal formulations in cancer therapy use 
polyethyleneglycol (PEG) to produce “stealth liposomes” with increased 
circulation properties. However, evidence increases about the 
antigenicity of PEG upon repeated injection leading to the so-called 
“accelerated blood clearance”. Our European collaboration succeeded to 
provide evidence that liposomes coated with a novel heparin conjugate 
do not lead to complement activation (Dührkop et al. 2016), which is 
considered to be a central component of rapid liposome clearance from 
the blood circulation. Current research focuses on in vitro and in vivo 
research to investigate possible advantages of liposomal formulation of 
mistletoe in a murine cancer model. In the following, results for the 
selection of murine cancer cell lines are presented which suitably respond 
to mistletoe compounds. 
European mistletoe (Viscum album L.) contains glycosylated proteins of 
type II ribosome-inactivating proteins (RIP II) (Barbieri et al. 1993, Stirpe 
2004), which can be differentiated into the 3 isoforms of ML I, ML II and 
ML III (Luther et al. 1987). ML are distributed in the parenchymal cells of 
the plant and inside of vacuoles, mostly in close contact with protein 
bodies (Blascheck et al., 2013). ML, viscotoxins (VT) and polysaccharides 
are major bioactive components of mistletoe extracts. The composition of 
mistletoe extracts depends on the species of the host tree, geographical 
location, and time of harvesting (Urech et al. 2006). ML I is a 63 kDa 
heterodimeric protein consisting of two chains, a toxic A-chain and a B-
chain. The toxic A-subunit is able to inactivate eukaryotic ribosomes via 
targeting the N-glycosidase activity, resulting in apoptotic cell death 
(Dietrich et al. 1992). The B-subunit of ML I recognizes specific terminal 
sugar residues of glycolipids and glycoproteins on the cell membrane 
and allows the toxic A-chain to enter into the target cell (Franz 1986). 
Extracts of mistletoe play an important role in adjuvant cancer 
therapy due to the improvement of the quality of life and the global 
health status of cancer patients (Kim et al. 2012, Eisenbraun et al. 2011, 
Kienle and Kiene 2010), which is attributed to their immune activating 
effect. The aim of this study was to determine the inhibitory effect of 
different AV preparations and isolated ML I in a dose-response 
experiment and to identify sensitive tumor cell lines for testing liposomal 
formulations of ML in animal models.  
The highly metastatic murine melanoma cell line B16-F10 and the 
metastatic murine colon carcinoma cell line C26 were tested regarding 
growth inhibition and cytotoxic effects by mistletoe extracts with 
different ML and VT compositions and isolated ML I.  
 
Materials and Methods 
Purification of mistletoe lectins and abnobaVISCUM 
extracts 
For protein isolation mistletoe was harvested in June from ash tree 
(Fraxinus excelsior L.) and extraction was performed as described 
previously (Eifler et al. 1993). 
Three different mistletoe preparations, AV Fraxini, Quercus and Pini 
were selected. ML I is the most characterized mistletoe lectin and 
generally regarded a major API in mistletoe extracts. The three selected 
preparations represent high and very low ML and VT contents, 
respectively, but also differ in their ML composition. For AV Fraxini and 
AV Quercus, ML I is the predominant lectin, whereas AV Pini almost 
exclusively contains ML III, as summarized in Table 1. 
 
Table 1. Differences in AV mistletoe lectin (ML) and viscotoxin (VT) 
composition and concentrations: 
 Host 
tree 
ML 
[µg/ml] 
VT 
[µg/ml] 
Concentration 
ratio VT/ML 
Predominant  
lectin 
AV Fraxini 20 mg ash 10.9 79.9 7.3 ML I 
AV Quercus 20 mg oak 8.4 66.4 7.9 ML I 
AV Pini 20 mg pine 0.27 1.2 4.4 ML III 
 
Cell lines 
The murine melanoma cell line B16-F10 was obtained from the 
American Type Culture Collection (ATCC No. 59123188, March 2013) 
and cultured in DMEM with high glucose supplemented with 10% heat-
inactivated FBS and sodium pyruvate. The murine C26 colon carcinoma 
cell line was kindly provided from O. Kranenburg, Med. Oncology UMC 
Utrecht CLS 400156 and cultured in RPMI1640 medium with 2 mM L-
glutamine and 10% heat-inactivated FBS. Cell cultures were handled 
under standard conditions (37°C, 5% CO2 and humid atmosphere) in cell 
culture media without added antibiotics. 
 
Cell proliferation assay 
The proliferation of cells was quantified by the colorimetric 
tetrazolium compound 3-(4,5 dimethylthiazol-2-yl)-5-(3-
carboxymethoxyphenyl)-2-(4-sulfophenyl)-2H-tetrazolium (MTS) and an 
electron coupling reagent phenazine ethosulfate (PES) combined in one 
assay (CellTiter 96®Aqueous One Solution Cell Proliferation Assay, 
Promega, Madison, USA) according to supplier´s instructions. 
B16-F10 and C26 cells were detached with trypsin, washed with 
phosphate buffered saline (PBS) and counted after incubation with 0.5% 
tryphan blue in a Bürker-Türk chamber. A defined number of cells was 
transferred into each well of a 96-well microtiter plate (Greiner, 
Frickenhausen, Germany). Cells were cultured for 24 h before incubation 
with AV Fraxini, Quercus, Pini (20 mg, respectively) or isolated ML I 
(concentration range from 10 pg/ml - 100 µg/ml) for 48 h. The AV dosage 
of 20 mg contains 15 mg homogenized extract from 20 mg mistletoe herb 
(fresh weight). Concentrations and IC50 for AV were calculated either 
based on mistletoe herb weight or based on ML concentration of AV (see 
Table 1). All ML concentrations were determined by ELISA. Control cells 
received DMEM or RPMI, depending on the type of cell line, as well as 
the same amount of phosphate ascorbic acid (PAA) or PBS buffer present 
in each dilution of tested AV preparations or isolated ML I, respectively. 
Each concentration was tested in quadruplicate wells. 
The MTS tetrazolium compound is bio-reduced by NADPH or 
NADH produced dehydrogenase enzymes in metabolically active cells 
into a colored formazan product that is soluble in tissue culture medium. 
Assays were performed by adding 20 µl of the CellTiter 96®Aqueous One 
Solution Reagent directly to the culture wells containing 100 µl of cell 
culture medium and incubated for 1 h under standard conditions. The 
quantity of formazan product was measured by absorbance at 490 nm 
(reference wavelength 630 nm) with a 96-well plate reader. The 
absorbance is directly proportional to the number of living cells in 
culture. Absorbance of control cells was taken as 100% and the AV or 
ML I-treated cells as percentage of survival. The IC50 was determined by 
non-linear regression analysis of dose response curves with GraphPad 
Prism. 
 
Results and Discussion 
In Figure 2, the results of the proliferation assay comparing different 
AV extracts are shown (melanoma cell line B16-F10). The results indicate 
that IC50 values for AV Fraxini and AV Quercus are 6 times lower 
compared to AV Pini. AV Fraxini and AV Quercus have high ML and VT 
concentrations and are, therefore, more cytotoxic than AV Pini, which 
was an expected result.  
 
Fig. 2: Proliferation of B16-F10 melanoma cells after 48 h incubation with 
abnobaVISCUM (AV) of different host trees. Concentrations and IC50 
values correspond to plant weight used for the extraction (= dose 
strength, see Materials and Methods). 
 
Interestingly, if the different extracts are compared in regard to their 
lectin concentration (Figure 3), AV Pini appears approx. 4 times more 
effective than the other two extracts. Since AV Pini almost exclusively 
contains ML III and VT concentration is low (most likely in a subtoxic 
range), the increase in effectiveness might potentially be attributed to 
ML III. However, other compounds in AV Pini, or a higher background 
of plant material due to lower dilutions of plant extract, may contribute 
to this effect.  
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Fig. 3: Comparison of AV extracts in regard to ML concentration (B16-
F10). 
 
Furthermore, B16-F10 and C26 were compared in regard to their 
sensitivity to isolated ML I (Figure 4 and Table 2). The colon carcinoma 
cell line C26 is the most sensitive of the cell lines tested with an IC50-
value in the low ng/ml range. The very aggressive melanoma cell line 
B16-F10 is markedly less sensitive, with IC50 values 45 times higher than 
those of C26.  
A comparison of ML I-rich mistletoe extracts (AV Fraxini, AV 
Quercus) and isolated ML I on B16-F10 show that the extract is approx. 
30% more effective than ML I (Figure 3 and Table 2). As abnobaVISCUM 
is a complex mixture of bioactives and also rich in viscotoxins, this result 
is expected. Regarding the direct anti-proliferative effect on tumor cells, 
it may be inferred that ML I is the major bioactive in AV Fraxini and AV 
Quercus. 
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Fig. 4: The effect of various concentrations of ML I on two different 
murine cell lines:  C26 colon cancer cells and ∆ B16-F10 melanoma cells. 
Presented curves were established from n = 2 independent experiments 
out of 2 independent extract batches of ML I and show the mean value ± 
standard deviation of 4 measured wells per experimental run, 
respectively. 
 
Table 2: IC50 of cell proliferation induced by extracts of ML I in murine 
cell lines. Numbers (± standard deviation) were established from n = 2 
independent experiments (presented in Fig. 4): 
 
Cell line C26 B16-F10 
Mouse strain BALB/c C57BL/6J 
IC50 ± SD of ML I [ng/ml] 3.4 ± 0.3 151.8 ± 14.0 
 
Conclusion 
By investigating anti-proliferative effect of different AV 
preparations, we found that the colon carcinoma cell line C26 is much 
more sensitive to isolated ML I than the very aggressive B16-F10 
melanoma cell line. This allows to compare a sensitive to a relatively non-
sensitive and more aggressive tumor cell line in animal models. Also, the 
inflammatory cell model RAW264.7 (macrophage) is comparatively 
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insensitive to isolated ML I (as we are about to show in Hildebrandt 
2016b), suggesting the possibility of selecting therapeutic concentrations 
that target e.g. colon tumours, but leave immune functions intact. 
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